BioAge Labs, Inc. BIOA
Set alert
5.87 USD -0.07 -1.18%
At close · Oct 30
5.87 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
5.63 Day range 5.93
4.84 52-week range 25.10
- YTD
- -55.63%
- 1 year
- -24.06%
- Open
- 5.86
- Prev close
- 5.94
- Mkt cap
- 269.41M
- Vol
- 801.36K
- Avg vol
- 964.44K
- EPS
- -2.39
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.63
- High
- 5.93
- Forward P/E
- -12.08
- Beta
- 0.00
- Short ratio
- 4.63
- Inst. own
- 85.48%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 18.87
- 200-d avg
- 15.13
- 1y target
- 49.50
2Y chart
Events in this range
- Aug 6, 2025Earnings: -0.6; estimate -0.56; surprise -7.14%
- Nov 6, 2025Earnings: -0.56; estimate -0.67; surprise 16.42%
- Feb 18, 2026Rating: Jefferies · Hold → Buy
- Feb 25, 2026Rating: Oppenheimer · — → Outperform
- Mar 10, 2026Rating: Citigroup · Buy → Buy
- Mar 24, 2026Earnings: -0.72; estimate -0.83; surprise 13.25%
- Mar 27, 2026Rating: Needham · — → Buy
- May 8, 2026Earnings: -0.52; estimate -0.63959; surprise 18.7%
- May 13, 2026Rating: BTIG · — → Buy
- May 27, 2026Rating: Roth Capital · — → Buy
- Aug 6, 2026Earnings: -0.58; estimate -0.60731; surprise 4.5%
Signals (82)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Sep 24, 2026 | 1 month ago |
| RSI: Oversold | Sep 18, 2026 | 1 month ago |
| RSI: Oversold | Sep 10, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 24, 2026 | 2 months ago |
| RSI: Oversold | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| RSI: Oversold | Jul 31, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| RSI: Overbought | Jun 23, 2026 | 4 months ago |
| SMA: Bullish | Jun 12, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| MACD: Buy Signal | May 29, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 22, 2026 | 6 months ago |
| SMA: Bullish | Apr 21, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 16, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 10, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 8, 2026 | 6 months ago |
| SMA: Bearish | Mar 20, 2026 | 7 months ago |
| SMA: Bullish | Mar 19, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 26, 2026 | 8 months ago |
| RSI: Overbought | Feb 26, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 26, 2026 | 9 months ago |
| RSI: Overbought | Jan 20, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 12, 2026 | 9 months ago |
| RSI: Overbought | Jan 12, 2026 | 9 months ago |
| RSI: Overbought | Jan 6, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 4, 2025 | 11 months ago |
| RSI: Overbought | Dec 4, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| RSI: Overbought | Nov 20, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 18, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 7, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 23, 2025 | 1 year ago |
| RSI: Overbought | Oct 23, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 9, 2025 | 1 year ago |
| RSI: Overbought | Sep 30, 2025 | 1 year ago |
| SMA: Bullish | Sep 17, 2025 | 1 year ago |
| SMA: Bullish | Aug 21, 2025 | 1 year ago |
| SMA: Bearish | Aug 19, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 15, 2025 | 1 year ago |
| SMA: Bullish | Aug 12, 2025 | 1 year ago |
| SMA: Bearish | Aug 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Aug 1, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| SMA: Bullish | Jul 2, 2025 | 1 year ago |
| SMA: Bearish | Jun 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 25, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 24, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | May 22, 2025 | 1 year ago |
| SMA: Bearish | May 21, 2025 | 1 year ago |
| SMA: Bullish | May 20, 2025 | 1 year ago |
| SMA: Bearish | May 13, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| MACD: Sell Signal | May 12, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | Apr 22, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| RSI: Oversold | Apr 2, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 27, 2025 | 1 year ago |
| RSI: Oversold | Jan 7, 2025 | 1 year ago |
| RSI: Oversold | Jan 2, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 24, 2024 | 1 year ago |
| RSI: Oversold | Dec 9, 2024 | 1 year ago |
Key statistics
- Market cap
- 1.11B
- Enterprise value
- 671.26M
- Trailing P/E
- 0.00
- Forward P/E
- -12.08
- PEG ratio
- 0.00
- Price / sales
- 107.25
- Price / book
- 2.91
- EPS (TTM)
- -2.40
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 10.32M
- Revenue growth
- 91.00%
- Free cash flow
- -58.34M
- Total cash
- 383.19M
- Total debt
- 4.03M
- Return on equity
- -25.98%
- Shares outstanding
- 44.45M
- Short % of float
- 5.06%
- 50-day average
- 18.87
- 200-day average
- 15.13
Analyst view
Consensus: none
Price target (mean) 49.50 +743.3% upside
Now 5.87
- Target (low)
- 23.00
- Target (mean)
- 49.50
- Target (high)
- 73.00
Ratings (0m) 9 7 buy · 2 hold · 0 sell
- Strong buy2
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.63167.
Financials — quick view
BIOA Revenue — quarterly 2.45M
BIOA Net income — quarterly -26.10M
BIOA EPS — quarterly -0.58
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.64142 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.60731 | -0.58 | +0.03 | +4.50% |
| May 8, 2026 | Mar 31, 2026 | -0.63959 | -0.52 | +0.12 | +18.70% |
| Mar 24, 2026 | Dec 31, 2025 | -0.83 | -0.72 | +0.11 | +13.25% |
| Nov 6, 2025 | Sep 30, 2025 | -0.67 | -0.56 | +0.11 | +16.42% |
| Aug 6, 2025 | Jun 30, 2025 | -0.56 | -0.60 | -0.04 | -7.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 27, 2026 | Roth Capital | init | — | Buy |
| May 13, 2026 | BTIG | init | — | Buy |
| Mar 27, 2026 | Needham | init | — | Buy |
| Mar 10, 2026 | Citigroup | main | Buy | Buy |
| Feb 25, 2026 | Oppenheimer | init | — | Outperform |
| Feb 18, 2026 | Jefferies | up | Hold | Buy |
About BioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- bioagelabs.com
News
- Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline
- BioAge Labs (NASDAQ:BIOA) and Royalty Pharma (NASDAQ:RPRX) Critical Comparison
- Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
- UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8
- Bank of America Corp DE Buys 257,855 Shares of BioAge Labs, Inc. $BIOA
- BioAge Labs to Present at Upcoming Investor Conferences
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema
Your note
Sign in to keep a note on BIOA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARTON SHANE | Officer | Sale | Jun 29, 2026 | 0 |
| CORMORANT ASSET MANAGEMENT ,L.P | Unknown | Purchase | Sep 26, 2024 | 0 |
| ENRIGHT PATRICK G. | Director | Purchase | Sep 26, 2024 | 0 |
| FORTNEY KRISTEN | Chief Executive Officer | Sale | Jan 12, 2026 | 976,949 |
| GOLDSTEIN DOV A | Chief Financial Officer | Conversion of Exercise of derivative security | Apr 22, 2026 | 36,575 |
| HEALY JAMES I | Director | Purchase | Sep 26, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| a16z Capital Management, L.L.C. | 7.27% | 3,233,170 | 80.47M | Mar 30, 2026 |
| Cormorant Asset Management, LP | 6.50% | 2,890,605 | 71.95M | Mar 30, 2026 |
| Sofinnova Investments, Inc. | 5.16% | 2,293,788 | 57.09M | Mar 30, 2026 |
| Blackrock Inc. | 5.10% | 2,267,756 | 56.44M | Mar 30, 2026 |
| Janus Henderson Group PLC | 4.71% | 2,094,270 | 52.13M | Mar 30, 2026 |
| Octagon Capital Advisors LP | 3.93% | 1,748,000 | 43.51M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.22% | 985,493 | 24.53M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.63% | 725,323 | 18.05M | May 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.76% | 336,229 | 8.37M | Mar 30, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.67% | 298,933 | 7.44M | Apr 29, 2026 |
| iShares Trust-iShares Russell 2000 Value ETF | 0.60% | 264,819 | 6.59M | May 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | 0.51% | 228,473 | 5.69M | May 30, 2026 |